111O - Impact of cardiac doses on survival of non-small cell lung cancer (NSCLC) patients following radical accelerated radiotherapy

Date 12 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session Limitations and advances of thoracic radiotherapy
Topics Lung and other Thoracic Tumours
Surgery and/or Radiotherapy of Cancer
Presenter matthew Hatton
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors M. Hatton1, S. Robinson1, J. Bradshaw2, S. Riley2, T. Das3, C. Lee3, P. Fisher3, E. Bates1, S. Tozer-Loft2, B. Tahir1
  • 1Clinical Oncology, Weston Park Hospital Cancer Research Centre, S10 2SJ - Sheffield/GB
  • 2Radiotherapy Physics, Weston Park Hospital Cancer Research Centre, S10 2SJ - Sheffield/GB
  • 3Clinial Oncology, Weston Park Hospital Cancer Research Centre, S10 2SJ - Sheffield/GB

Abstract

RTOG 0617 identified cardiac dose-volume metrics as independent predictors of survival for locally advanced NSCLC patients following chemoradiotherapy with conventional and dose escalated regimes. Accelerated radiotherapy schedules such as continuous hyperfractionated accelerated radiotherapy (CHART) are widespread in the UK. In this single-centre retrospective analysis, we study the impact of cardiac dosimetry on survival of early stage and locally advanced patients radically treated with accelerated radiotherapy.